Dots is a technology company.
Dots provides automation and insights for Discord and Slack, helping communities enhance member experiences through interactive onboarding and detailed analytics.
| Investor | Firm Type | Partner |
|---|---|---|
DCMLEAD |
| Venture Capital |
| — |
This company has completed 4 funding rounds. Current round is highlighted.
Total Raised
$30.8M
Top Valuation
-
Dots raised $8.9M in a Early Stage Venture round.
The round was led by DCM.
DOTS Technology Corp (also known as DOTS or Detection On The Spot) is a health tech company founded in 2013 that develops a diagnostics platform focused on point-of-care detection, primarily a consumer food allergen detector to test food for allergens before consumption.[1][4][5] Headquartered in Natick, Massachusetts, it has raised $30.9M in total funding through a Series B round, with investors including New Enterprise Associates, Alumni Ventures, and Felicis, and holds a granted patent for allergen detection technology.[1][4] The product serves consumers with food allergies, solving the problem of unsafe food intake by providing rapid, at-home testing to inform dietary decisions, positioning it in the growing healthcare diagnostics sector.[1][5]
While other entities share the "Dots" name—like Dots Tech for IT logistics/asset management and Dots Technologies for IT development—search results confirm DOTS as the primary match for a technology company with significant funding and patents in consumer health diagnostics.[1][2][3]
DOTS was founded in 2013 in Natick, Massachusetts, by a team aiming to revolutionize point-of-care diagnostics in healthcare.[1][4] The core idea emerged from addressing gaps in food allergen detection, leading to their first product: a consumer-facing device that detects allergens in food using advanced biotech methods, supported by a key patent filed in 2014 and granted in 2019 for "Allergen detection" involving molecular biology and DNA techniques.[1] Early traction included securing $30.9M in funding, with a $20.89M Series B round about 8 years ago, backed by prominent VCs like New Enterprise Associates, signaling pivotal validation in the health tech space.[1][5]
DOTS rides the wave of personalized health tech and point-of-care diagnostics, a trend accelerated by rising food allergy prevalence (affecting ~32M Americans) and demand for consumer empowerment post-pandemic.[1][5] Timing aligns with biotech advances in portable DNA testing, making at-home allergen detection feasible amid market forces like regulatory pushes for food safety and growth in the $50B+ diagnostics industry. By enabling proactive consumer decisions, DOTS influences the ecosystem, potentially inspiring similar devices for other allergens or industrial uses, while bridging health tech with everyday consumer products.[1][4][5]
DOTS is poised to capitalize on expanding at-home health diagnostics, potentially launching commercial products or new applications beyond food allergens, driven by its patented tech and investor support.[1][5] Trends like AI-enhanced biotech and global allergy awareness will shape its path, with influence evolving toward broader point-of-care solutions if it overcomes scaling hurdles from its last funding 8 years ago. This positions DOTS as a key player in making diagnostics accessible, tying back to its mission of safer food decisions through innovative detection.[1][4]